Intramers and Aptamers: Applications in Protein‐Function Analyses and Potential for Drug Screening

During the past decade, the complete genomes of more than 140 different organisms have been sequenced and made available in databases. These databases provide extremely useful collections of organised, validated data, which are indispensable for genomics and proteomics research and the drugdiscovery process. Differential analyses of pathogenic and healthy states of organisms and/or isolated cells provide a picture of genes and gene products that are related to, or actually responsible for, defined diseases. The challenge today is to understand in detail the function and interplay of the numerous proteins in different organisms, tissues, cell types and conglomerate protein complexes. Among the most effective ways to study the function of a given protein in the context of the living cell or organism is the application of a small-molecule drug that exhibits high specificity, affinity and inhibitory activity for the protein under investigation. However, because such inhibitors are available only for a minority of the estimated total number of proteins of higher vertebrate organisms, protein function is most commonly studied by loss-of-function phenotypic analysis.

[1]  E. Luzi,et al.  Designing ribozymes for the inhibition of gene expression. , 1998, Trends in biotechnology.

[2]  D. Bartel,et al.  Selective optimization of the Rev-binding element of HIV-1. , 1993, Nucleic acids research.

[3]  M. Nóbrega,et al.  Comparative genomics at the vertebrate extremes , 2004, Nature Reviews Genetics.

[4]  H. U. Göringer,et al.  In vitro selection of high-affinity nucleic acid ligands to parasite target molecules. , 2003, International journal for parasitology.

[5]  A. Ellington,et al.  Polyvalent Rev Decoys Act as Artificial Rev-Responsive Elements , 1999, Journal of Virology.

[6]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[7]  M. Famulok,et al.  IN-VITRO-SELEKTION SPEZIFISCH LIGANDENBINDENDER NUCLEINSAUREN , 1992 .

[8]  M. Famulok,et al.  Discriminatory aptamer reveals serum response element transcription regulated by cytohesin-2. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Michael T. McManus,et al.  Gene silencing in mammals by small interfering RNAs , 2002, Nature Reviews Genetics.

[10]  U. Schepers,et al.  RNA interference: from an ancient mechanism to a state of the art therapeutic application? , 2003, Naturwissenschaften.

[11]  L. Cassiday,et al.  Yeast genetic selections to optimize RNA decoys for transcription factor NF-κB , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. H. Burke,et al.  Expressing RNA aptamers inside cells to reveal proteome and ribonome function. , 2002, Briefings in functional genomics & proteomics.

[13]  L. Cassiday,et al.  In vivo recognition of an RNA aptamer by its transcription factor target. , 2001, Biochemistry.

[14]  J C Cox,et al.  Automated selection of anti-protein aptamers. , 2001, Bioorganic & medicinal chemistry.

[15]  Nebojsa Janjic,et al.  Inhibitory DNA ligands to platelet-derived growth factor B-chain. , 1996, Biochemistry.

[16]  T. Tuschl,et al.  RNA Interference and Small Interfering RNAs , 2001, Chembiochem : a European journal of chemical biology.

[17]  J. Claverie,et al.  What If There Are Only 30,000 Human Genes? , 2001, Science.

[18]  Razvan Nutiu,et al.  Signaling Aptamers for Monitoring Enzymatic Activity and for Inhibitor Screening , 2004, Chembiochem : a European journal of chemical biology.

[19]  Amy C Yan,et al.  Protein-dependent ribozymes report molecular interactions in real time , 2002, Nature Biotechnology.

[20]  A. Hüttenhofer,et al.  In vitro and in vivo characterization of novel mRNA motifs that bind special elongation factor SelB. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Cairns,et al.  Catalytic DNA: a novel tool for gene suppression. , 2002, Current drug targets.

[22]  Phillip A. Sharp,et al.  The RNAi revolution , 2004, Nature.

[23]  R. Jenison,et al.  High-throughput ribozyme-based assays for detection of viral nucleic acids. , 2004, Chemistry & biology.

[24]  R. Treisman,et al.  The Rho family GTPases RhoA, Racl , and CDC42Hsregulate transcriptional activation by SRF , 1995, Cell.

[25]  B. Stockwell.  Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.

[26]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[27]  J. KlugS,et al.  特異な延長因子SelBに結合する新規mRNAモチーフのin vitro及びin vivoにおける性質 , 1997 .

[28]  Michael Famulok,et al.  All you wanted to know about SELEX , 2004, Molecular Biology Reports.

[29]  G. Hannon.  RNA interference : RNA , 2002 .

[30]  R. Strausberg,et al.  From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes , 2003, Science.

[31]  M. Famulok,et al.  Sensing complex regulatory networks by conformationally controlled hairpin ribozymes. , 2004, Nucleic acids research.

[32]  M Yarus,et al.  Diversity of oligonucleotide functions. , 1995, Annual review of biochemistry.

[33]  A. Branch,et al.  A good antisense molecule is hard to find , 1998 .

[34]  Andrew Ellington,et al.  In vitro selection of an allosteric ribozyme that transduces analytes to amplicons , 1999, Nature Biotechnology.

[35]  D. H. Burke,et al.  Inhibition of HIV-1 reverse transcriptase by RNA aptamers in Escherichia coli. , 2003, RNA.

[36]  T. Böhm,et al.  Controlling small guanine–nucleotide-exchange factor function through cytoplasmic RNA intramers , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Famulok,et al.  Oligonucleotide aptamers that recognize small molecules. , 1999, Current opinion in structural biology.

[38]  External Regulation of Hairpin Ribozyme Activity by an Oligonucleotide Effector , 2003, Chembiochem : a European journal of chemical biology.

[39]  Herbert Waldmann,et al.  From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. , 2002, Angewandte Chemie.

[40]  Herbert Waldmann,et al.  From protein domains to drug candidates – natural products as guiding principles in , 2002 .

[41]  Timothy J Mitchison,et al.  Small molecules, big impact: a history of chemical inhibitors and the cytoskeleton. , 2002, Chemistry & biology.

[42]  B. Seed,et al.  αLβ2 Integrin/LFA-1 Binding to ICAM-1 Induced by Cytohesin-1, a Cytoplasmic Regulatory Molecule , 1996, Cell.

[43]  In vitro selection of RNA aptamers that bind special elongation factor SelB, a protein with multiple RNA-binding sites, reveals one major interaction domain at the carboxyl terminus. , 1999, RNA.

[44]  Jeff Zimmerman,et al.  Crystal structure of NF-κB (p50)2 complexed to a high-affinity RNA aptamer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Michael Famulok,et al.  Reporter ribozymes for real-time analysis of domain-specific interactions in biomolecules: HIV-1 reverse transcriptase and the primer-template complex. , 2002, Angewandte Chemie.

[46]  A. Ellington,et al.  Aptamers as potential nucleic acid pharmaceuticals. , 1995, Biotechnology annual review.

[47]  R. Plasterk,et al.  Dicers at RISC The Mechanism of RNAi , 2004, Cell.

[48]  M. Famulok,et al.  Nucleic acid aptamers-from selection in vitro to applications in vivo. , 2000, Accounts of chemical research.

[49]  G. Ferbeyre,et al.  Expressing active ribozymes in cells. , 2000, Current issues in molecular biology.

[50]  Georg Sczakiel,et al.  Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. , 2002, Nucleic acids research.

[51]  B. Polisky,et al.  Zeptomole detection of a viral nucleic acid using a target-activated ribozyme. , 2003, RNA.

[52]  Michael Famulok,et al.  In Vitro Selection of Specific Ligand‐binding Nucleic Acids , 1992 .

[53]  John J Rossi,et al.  Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase , 2004, Nature Biotechnology.

[54]  M. Kurz,et al.  ADP-specific sensors enable universal assay of protein kinase activity. , 2004, Chemistry & biology.

[55]  G. F. Joyce,et al.  In vitro evolution of nucleic acids. , 1994, Current opinion in structural biology.

[56]  H. Steinhoff,et al.  HIV-1 Reverse Transcriptase-Pseudoknot RNA Aptamer Interaction Has a Binding Affinity in the Low Picomolar Range Coupled with High Specificity* , 2000, The Journal of Biological Chemistry.

[57]  M. Gerstein,et al.  A question of size: the eukaryotic proteome and the problems in defining it. , 2002, Nucleic acids research.

[58]  J. Casanova,et al.  GTPase Signaling: Bridging the GAP between ARF and Rho , 2002, Current Biology.

[59]  H. Waldmann,et al.  Von Proteindomänen zu Wirkstoffkandidaten - Naturstoffe als Leitstrukturen für das Design und die Synthese von Substanzbibliotheken , 2002 .

[60]  M. Famulok,et al.  Intramers as promising new tools in functional proteomics. , 2001, Chemistry & biology.

[61]  G. Powis,et al.  Inhibition of growth factor binding, Ca2+ signaling and cell growth by polysulfonated azo dyes related to the antitumor agent suramin , 2004, Cancer Chemotherapy and Pharmacology.

[62]  M. Famulok,et al.  Cytoplasmic RNA modulators of an inside-out signal-transduction cascade. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Yang Li,et al.  Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. , 2002, Antisense & nucleic acid drug development.

[64]  R. Cedergren,et al.  Efficient hammerhead ribozyme and antisense RNA targeting in a slow ribosome Escherichia colimutant , 1997, Nature Biotechnology.

[65]  J. Wills,et al.  Isolation of virus-neutralizing RNAs from a large pool of random sequences. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[66]  F. Liu,et al.  In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection. , 2000, RNA.

[67]  J. Rossi.  Ribozymes, genomics and therapeutics. , 1999, Chemistry & biology.

[68]  J C Cox,et al.  Automated RNA Selection , 1998, Biotechnology progress.

[69]  Satoshi Nishikawa,et al.  Inhibition of HCV NS3 protease by RNA aptamers in cells. , 2003, Nucleic acids research.

[70]  Michael Famulok,et al.  In vivo-applied functional RNAs as tools in proteomics and genomics research. , 2002, Trends in biotechnology.

[71]  Jens Kurreck,et al.  Antisense technologies. Improvement through novel chemical modifications. , 2003, European journal of biochemistry.

[72]  R. Breaker,et al.  Genetic Control by Metabolite‐Binding Riboswitches , 2003, Chembiochem : a European journal of chemical biology.

[73]  J. Rossi,et al.  Intracellular ribozyme applications. , 2001, Biochemical Society transactions.

[74]  L. Gold,et al.  RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Thomas Tuschl,et al.  siRNAs: applications in functional genomics and potential as therapeutics , 2004, Nature Reviews Drug Discovery.

[76]  A. Schmidt,et al.  Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. , 1999, Methods in enzymology.

[77]  C. Carles,et al.  Selective Targeting and Inhibition of Yeast RNA Polymerase II by RNA Aptamers* , 1997, The Journal of Biological Chemistry.

[78]  Yingfu Li,et al.  Structure-switching signaling aptamers. , 2003, Journal of the American Chemical Society.

[79]  Michael Famulok,et al.  Sequence-specific detection of MicroRNAs by signal-amplifying ribozymes. , 2004, Journal of the American Chemical Society.

[80]  Walter A. Korfmacher,et al.  Rapid determination of pharmacokinetic properties of new chemical entities: in vivo approaches. , 2002, Combinatorial chemistry & high throughput screening.

[81]  Jörg S. Hartig Dipl.-Chem.,et al.  Reporter Ribozymes for Real-Time Analysis of Domain-Specific Interactions in Biomolecules: HIV-1 Reverse Transcriptase and the Primer–Template Complex† , 2002 .

[82]  Y. Chen,et al.  Intracellular production of DNA enzyme by a novel single-stranded DNA expression vector , 2003, Gene Therapy.

[83]  J. Rossi.  Controlled, targeted, intracellular expression of ribozymes: progress and problems. , 1995, Trends in biotechnology.

[84]  M. Huynen,et al.  Prediction of protein function and pathways in the genome era , 2004, Cellular and Molecular Life Sciences CMLS.

[85]  J. Rossi,et al.  Intracellular applications of ribozymes. , 2001, Methods in enzymology.

[86]  D. Patel,et al.  Adaptive recognition by nucleic acid aptamers. , 2000, Science.

[87]  Sunjoo Jeong,et al.  Inhibition of the functions of the nucleocapsid protein of human immunodeficiency virus-1 by an RNA aptamer. , 2004, Biochemical and biophysical research communications.

[88]  C. Crews,et al.  Chemical genetics: exploring and controlling cellular processes with chemical probes. , 1999, Trends in biochemical sciences.

[89]  J. Lis,et al.  RNA aptamers as effective protein antagonists in a multicellular organism. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[90]  F. Ruddle,et al.  Impact of transgenic technologies on functional genomics. , 2003, Current issues in molecular biology.